Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) was the target of a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 1,061,697 shares, a growth of 29.3% from the August 15th total of 821,241 shares. Based on an average trading volume of 151,075 shares, the short-interest ratio is currently 7.0 days. Currently, 6.8% of the company’s shares are short sold.
Separately, HC Wainwright set a $6.00 price target on shares of Ampliphi Biosciences and gave the company a “buy” rating in a research note on Wednesday, May 16th.
A hedge fund recently bought a new stake in Ampliphi Biosciences stock. Sabby Management LLC bought a new position in shares of Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 831,961 shares of the biotechnology company’s stock, valued at approximately $907,000. Sabby Management LLC owned 5.05% of Ampliphi Biosciences as of its most recent SEC filing.
Shares of Ampliphi Biosciences stock traded up $0.05 on Wednesday, reaching $1.01. The company had a trading volume of 231,979 shares, compared to its average volume of 341,290. Ampliphi Biosciences has a 52-week low of $0.82 and a 52-week high of $2.05.
Ampliphi Biosciences (NYSEAMERICAN:APHB) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.01. Ampliphi Biosciences had a negative net margin of 2,050.00% and a negative return on equity of 31.85%.
About Ampliphi Biosciences
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.
Recommended Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.